Literature DB >> 28235761

High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis.

Ryan J Hartmaier1, Lee A Albacker2, Juliann Chmielecki2, Mark Bailey2, Jie He2, Michael E Goldberg2, Shakti Ramkissoon2, James Suh2, Julia A Elvin2, Samuel Chiacchia2, Garrett M Frampton2, Jeffrey S Ross2,3, Vincent Miller2, Philip J Stephens2, Doron Lipson1.   

Abstract

Genomic profiling is widely predicted to become a standard of care in clinical oncology, but more effective data sharing to accelerate progress in precision medicine will be required. Here, we describe cancer-associated genomic profiles from 18,004 unique adult cancers. The dataset was composed of 162 tumor subtypes including multiple rare and uncommon tumors. Comparison of alteration frequencies to The Cancer Genome Atlas identified some differences and suggested an enrichment of treatment-refractory samples in breast and lung cancer cohorts. To illustrate novelty within the dataset, we surveyed the genomic landscape of rare diseases and identified an increased frequency of NOTCH1 alterations in adenoid cystic carcinomas compared with previous studies. Analysis of tumor suppressor gene patterns revealed disease specificity for certain genes but broad inactivation of others. We identified multiple potentially druggable, novel and known kinase fusions in diseases beyond those in which they are currently recognized. Analysis of variants of unknown significance identified an enrichment of SMAD4 alterations in colon cancer and other rare alterations predicted to have functional impact. Analysis of established, clinically relevant alterations highlighted the spectrum of molecular changes for which testing is currently recommended, as well as opportunities for expansion of indications for use of approved targeted therapies. Overall, this dataset presents a new resource with which to investigate rare alterations and diseases, validate clinical relevance, and identify novel therapeutic targets. Cancer Res; 77(9); 2464-75. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28235761     DOI: 10.1158/0008-5472.CAN-16-2479

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

2.  Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.

Authors:  Christopher R McEvoy; Huiling Xu; Kortnye Smith; Dariush Etemadmoghadam; Huei San Leong; David Y Choong; David J Byrne; Amir Iravani; Sophie Beck; Linda Mileshkin; Richard W Tothill; David D Bowtell; Bindi M Bates; Violeta Nastevski; Judy Browning; Anthony H Bell; Chloe Khoo; Jayesh Desai; Andrew P Fellowes; Stephen B Fox; Owen Wj Prall
Journal:  J Clin Invest       Date:  2019-03-05       Impact factor: 14.808

3.  Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Authors:  Ethan S Sokol; Dean Pavlick; Garrett M Frampton; Jeffrey S Ross; Vincent A Miller; Siraj M Ali; Tamara L Lotan; Drew M Pardoll; Jon H Chung; Emmanuel S Antonarakis
Journal:  Oncologist       Date:  2019-07-10

Review 4.  The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

Authors:  Valentina De Falco; Francesca Carlomagno; Hong-Yu Li; Massimo Santoro
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-05-10       Impact factor: 4.690

5.  Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.

Authors:  Alexa B Schrock; Dean Pavlick; Samuel J Klempner; Jon H Chung; Brady Forcier; Allison Welsh; Lauren Young; Bryan Leyland-Jones; Rodolfo Bordoni; Richard D Carvajal; Joseph Chao; Razelle Kurzrock; Jason K Sicklick; Jeffrey S Ross; Philip J Stephens; Craig Devoe; Fadi Braiteh; Siraj M Ali; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2018-01-23       Impact factor: 12.531

6.  Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.

Authors:  Kanika Bajaj Pahuja; Thong T Nguyen; Bijay S Jaiswal; Kumar Prabhash; Tarjani M Thaker; Kate Senger; Subhra Chaudhuri; Noelyn M Kljavin; Aju Antony; Sameer Phalke; Prasanna Kumar; Marco Mravic; Eric W Stawiski; Derek Vargas; Steffen Durinck; Ravi Gupta; Arati Khanna-Gupta; Sally E Trabucco; Ethan S Sokol; Ryan J Hartmaier; Ashish Singh; Anuradha Chougule; Vaishakhi Trivedi; Amit Dutt; Vijay Patil; Amit Joshi; Vanita Noronha; James Ziai; Sripad D Banavali; Vedam Ramprasad; William F DeGrado; Raphael Bueno; Natalia Jura; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2018-10-25       Impact factor: 31.743

7.  Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors.

Authors:  Ryan N Ptashkin; Diana L Mandelker; Catherine C Coombs; Kelly Bolton; Zarina Yelskaya; David M Hyman; David B Solit; José Baselga; Maria E Arcila; Marc Ladanyi; Liying Zhang; Ross L Levine; Michael F Berger; Ahmet Zehir
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

Review 8.  TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Authors:  Shivaani Kummar; Ulrik N Lassen
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

9.  Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Authors:  Jacqulyne P Robichaux; Yasir Y Elamin; R S K Vijayan; Monique B Nilsson; Lemei Hu; Junqin He; Fahao Zhang; Marlese Pisegna; Alissa Poteete; Huiying Sun; Shuai Li; Ting Chen; Han Han; Marcelo Vailati Negrao; Jordi Rodon Ahnert; Lixia Diao; Jing Wang; Xiuning Le; Funda Meric-Bernstam; Mark Routbort; Brent Roeck; Zane Yang; Victoria M Raymond; Richard B Lanman; Garrett M Frampton; Vincent A Miller; Alexa B Schrock; Lee A Albacker; Kwok-Kin Wong; Jason B Cross; John V Heymach
Journal:  Cancer Cell       Date:  2019-10-03       Impact factor: 31.743

10.  Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

Authors:  Natalie I Vokes; David Liu; Biagio Ricciuti; Elizabeth Jimenez-Aguilar; Hira Rizvi; Felix Dietlein; Meng Xiao He; Claire A Margolis; Haitham A Elmarakeby; Jeffrey Girshman; Anika Adeni; Francisco Sanchez-Vega; Nikolaus Schultz; Suzanne Dahlberg; Ahmet Zehir; Pasi A Jänne; Mizuki Nishino; Renato Umeton; Lynette M Sholl; Eliezer M Van Allen; Matthew D Hellmann; Mark M Awad
Journal:  JCO Precis Oncol       Date:  2019-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.